Drug Trial Radar · NCT06562946
The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function
Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Sep 20, 2024
Primary completion
Dec 30, 2024
Study completion Jan 10, 2025
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, open-label, parallel-group, single-center study to evaluate the pharmacokinetics and safety of a single 25 mg oral dose of pimicotinib in subjects with mild and moderate hepatic impairment and in control subjects with normal hepatic function.
Conditions
- Pharmacokinetics
Interventions
PimicotinibDrug
Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Conduct testing within 2 month after all subjects collect all samples at all time points required by the protocol
- AUClastTime frame: Conduct testing within 2 month after all subjects collect all samples at all time points required by the protocol
- AUC 0-∞Time frame: Conduct testing within 2 month after all subjects collect all samples at all time points required by the protocol
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The first hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.